Woodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Woodline Partners LP trimmed its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 70.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 301,335 shares of the biopharmaceutical company's stock after selling 726,952 shares during the quarter. Woodline Partners LP owned about 0.10% of Amicus Therapeutics worth $2,839,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. HealthInvest Partners AB lifted its stake in shares of Amicus Therapeutics by 18.6% in the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company's stock worth $3,076,000 after buying an additional 51,368 shares during the last quarter. Tempus Wealth Planning LLC acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth $259,000. Intech Investment Management LLC lifted its stake in shares of Amicus Therapeutics by 59.7% in the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock worth $1,175,000 after buying an additional 46,633 shares during the last quarter. Norges Bank acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth $29,033,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Amicus Therapeutics by 174.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock worth $19,863,000 after buying an additional 1,339,316 shares during the last quarter.

Analysts Set New Price Targets

FOLD has been the subject of a number of analyst reports. Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. The Goldman Sachs Group cut their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. UBS Group upped their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Wells Fargo & Company cut their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Price Performance

Shares of FOLD stock traded down $0.07 during mid-day trading on Friday, reaching $6.15. The company's stock had a trading volume of 484,619 shares, compared to its average volume of 2,873,769. Amicus Therapeutics, Inc. has a 1-year low of $5.81 and a 1-year high of $12.65. The company has a market cap of $1.89 billion, a P/E ratio of -34.14, a PEG ratio of 1.51 and a beta of 0.64. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The firm's 50-day moving average is $6.89 and its two-hundred day moving average is $8.61.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.